Stocksigma LogoStocksigma Logo

Granules India Outlines Business Transformation and High-Value Growth Drivers

Granules India scheduled a webinar on 29th Sep'26 with IIFL Capital to discuss its strategic transition beyond legacy generics

Granules India Outlines Business Transformation and High-Value Growth Drivers

Granules India Ltd · Intimation · 27 Sept 2026, 1:41 am

Granules India Outlines Business Transformation and High-Value Growth Drivers Granules India scheduled a webinar on 29th Sep'26 with IIFL Capital to discuss its strategic transition beyond legacy generics. Formulations now generate ~75% of revenue, with legacy-5 portfolio dependence dropping from ~85% in FY23 to <50% in FY26. Future growth centers on controlled substances, complex formulations, injectables, oncology (with potential 180-day exclusivities from FY28), US FTF/Para IV opportunities, and its Senn-backed peptide CDMO platform targeting a USD 100m revenue opportunity over 4–5 years to drive margin expansion.

Original exchange filing (PDF)

More announcements from Granules India Ltd

All Granules India Ltd announcements